


# Cambridge Biotechnology Limited

## Annual report and financial statements

Registered number 04221335

31 December 2020



## **Contents**

<b>Company information</b>	<b>1</b>
<b>Directors' report</b>	<b>2</b>
<b>Statement of income and retained earnings</b>	<b>3</b>
<b>Balance sheet</b>	<b>4</b>
<b>Notes</b>	<b>5</b>

## **Company information**

### **Directors**

Chad Martinson  
Mark Evenstad

### **Registered number**

04221335

### **Registered office**

5 New Street Square  
London EC4A 3TW  
United Kingdom

## **Directors' report**

The directors present their report and the financial statements for the year ended 31 December 2020.

### **Principal activities**

The Company did not trade in the current year.

### **Directors**

The directors who served during the year and up to the date of this report were:

Chad Martinson  
Mark Evenstad


### **Audit**

For the year ending 31 December 2020 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

### **Small company provisions**

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the board on 22 September 2021 and signed on its behalf by:



**Chad Martinson**  
*Director*

**Statement of income and retained earnings**  
*for the year ended 31 December 2020*

	Year to 31 Dec 20 £000	Year to 31 Dec 19 £000
Turnover	-	-
Administrative expenses	-	-
<b>Loss for the year</b>	-	-
Retained loss brought forward	-	-
<b>Retained loss carried forward</b>	-	-

The company has not traded during the current year.

There were no recognised gains or losses in either the current or preceding year and therefore no separate statement of other comprehensive income has been presented.

**Balance sheet**  
as at 31 December 2020

	Note	2020 £000	2019 £000
<b>Current assets</b>		-	-
<b>Net assets</b>		-	-
<b>Creditors: amounts falling due within one year</b>		-	-
<b>Net current liabilities</b>		-	-
<b>Net liabilities</b>		-	-
<b>Capital and reserves</b>			
Called up share capital	2	3,456	3,456
Share premium account	3	7,115	7,115
Profit and loss account	4	(10,571)	(10,571)
<b>Shareholders' deficit</b>	5	-	-


The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

For the year ended 31 December 2020 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

**Directors' responsibilities:**

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements were approved and authorised for issue by the board on 22 September 2021 and were signed on its behalf by:



**Chad Martinson**  
Director

## Notes

*(forming part of the financial statements)*

### 1 Accounting policies

Cambridge Biotechnology Limited (the "Company") is a private company incorporated, domiciled and registered in England in the UK. The registered number is 04221335 and the registered address is 5 New Street Square, London EC4A 3TW.

These financial statements were prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland ("FRS 102") as issued in August 2015. The amendments to FRS 102 issued in July 2016 and effective immediately have been applied and are effective immediately. In the transition to FRS 102 from old UK GAAP, the Company has made no measurement and recognition adjustments and taken advantage of the permitted exemptions to retain the existing accounting policies and account balances until the date at which a new accounting transaction is recognised.

There are no judgements made by the directors, in the application of these accounting policies that have significant effect on the financial statements and no estimates with a significant risk of material adjustment in the next year.

#### 1.1. Measurement convention

The financial statements are prepared on the historical cost basis.

#### 1.2. Going concern

The financial statements of Cambridge Biotechnology Limited ("the Company") have been prepared on a going concern basis in accordance with applicable UK accounting standards, under the historical cost convention and in accordance with Companies Act 2006.

#### 1.3. Deferred Taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

### 2. Called up share capital

	31 December 2020	31 December 2019
Authorised, issued and fully paid:	£'000	£'000
3,456,390 (31 December 2015: 3,456,390) Ordinary shares of £1 each	3,456	3,456

### 3. Share premium account

	31 December 2020	31 December 2019
	£'000	£'000
Opening and closing share premium account	7,115	7,115

### 4. Profit and loss account

	31 December 2020	31 December 2019
	£'000	£'000
Opening profit and loss reserves	(10,571)	(10,571)
Profit/(Loss) for the financial year	-	-
Closing profit and loss reserves	<u>(10,571)</u>	<u>(10,571)</u>

**5. Reconciliation of movement in shareholders' funds**

	<b>31 December 2020</b>	<b>31 December 2019</b>
	<b>£'000</b>	<b>£'000</b>
Opening shareholders' funds	-	-
Profit/(Loss) for the financial year	-	-
Closing shareholders' funds	-	-

**6. Ultimate parent undertaking**

The Company's immediate parent undertaking is Proximagen, LLC, a company registered in the state of Delaware, United States of America.